Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ziconotide (Elan Pharmaceuticals).

IDrugs : the investigational drugs journal·2005
Same author

Common ground in therapy of substance abuse.

IDrugs : the investigational drugs journal·2005
Same author

Glycine absorption from the small intestines of rats after secondary infections with Eimeria nieschulzi.

Experientia·1986
Same author

Intestinal absorption studies with glycyl-proline, glycine and ethanol in rats infected with Eimeria nieschulzi.

Life sciences·1985
Same author

Glycylproline absorption in rats infected with Eimeria nieschulzi.

Biochemical Society transactions·1981
Same author

Absorption of glycine and proline from the small intestine of rats infected with Eimeria nieschulzi.

Experientia·1980

Related Experiment Video

Updated: Jul 5, 2026

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

AD-5423 Dainippon Pharmaceutical Co Ltd.

C E Heading

    Idrugs : the Investigational Drugs Journal
    |May 10, 2008
    PubMed
    Summary

    AD-5423, a D(2)/5-HT2 antagonist, is well-tolerated in healthy volunteers and shows no extrapyramidal side effects. This antipsychotic drug is being developed for schizophrenia and other psychoses.

    Area of Science:

    • Pharmacology
    • Neuroscience
    • Clinical Trials

    Background:

    • Schizophrenia and related psychoses are significant public health challenges.
    • Novel therapeutic agents targeting dopamine D(2) and serotonin 5-HT2 receptors are under investigation.
    • AD-5423 is an investigational drug with combined D(2)/5-HT2 antagonist properties.

    Purpose of the Study:

    • To evaluate the safety and tolerability of AD-5423 in a phase I clinical trial.
    • To assess potential adverse effects, including extrapyramidal symptoms, sedation, and hypotension.

    Main Methods:

    • A phase I clinical study was conducted in eight healthy volunteers.
    • Administration of AD-5423 and monitoring for adverse events.

    Main Results:

    More Related Videos

    Environmental Modulations of the Number of Midbrain Dopamine Neurons in Adult Mice
    09:35

    Environmental Modulations of the Number of Midbrain Dopamine Neurons in Adult Mice

    Published on: January 20, 2015

    Related Experiment Videos

    Last Updated: Jul 5, 2026

    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
    06:08

    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

    Published on: March 11, 2017

    Environmental Modulations of the Number of Midbrain Dopamine Neurons in Adult Mice
    09:35

    Environmental Modulations of the Number of Midbrain Dopamine Neurons in Adult Mice

    Published on: January 20, 2015

    • AD-5423 was found to be well-tolerated in the study participants.
    • No significant extrapyramidal side effects, excessive sedation, or hypotension were observed.

    Conclusions:

    • AD-5423 demonstrates a favorable safety profile in healthy volunteers.
    • These findings support further investigation of AD-5423 in phase II trials for schizophrenia and psychoses.